New 25-Valent pneumonia vaccine shows promise in phase 2 trial
NCT ID NCT06077656
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine designed to protect against 25 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 220 healthy adults aged 18 to 49 received either the new vaccine or an existing one to compare safety and immune response. The goal is to see if the new vaccine is safe and triggers a strong immune reaction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL VACCINES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inventprise Clinical Site
Vancouver, British Columbia, V5Z 4H4, Canada
-
Inventprise Clinical Site
Halifax, Nova Scotia, B3K 6R8, Canada
-
Inventprise Clinical Site
Truro, Nova Scotia, B2N IL2, Canada
-
Inventprise Clinical Site
Saint-Louis, Quebec, G1W 4R4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine targets 26 pneumococcal strains in early trial
- New pneumonia vaccine VAX-31 aims to boost protection in older adults
- New combo shot study: could VAX-31 plus flu vaccine be a Game-Changer for seniors?
- Can a pneumonia vaccine protect the most vulnerable children?
- New vaccine aims to outsmart pneumonia bacteria
- New baby vaccine aims to beat pneumonia: VAX-31 trial underway